Home

Sanofi

CIK 1121404 · last filed 2021-09-14

Sanofi is a corporate insider who has filed 65 SEC Form 4 insider transactions across 11 companies since 2011. The most recent filing shows the insider bought $2.74B of TBIO on Sep 14, 2021. Across all open-market trades the lifetime net is −$2.44B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.56B across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.56B

Companies

11

Total Filings

65

Lifetime Open-Market Net

-$2.44B

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Translate Bio, Inc. (TBIO) Delisted 10%+ Owner 3,064,003 $0.00 $306 $2.74B 1 2021-09-14
Icosavax, Inc. (ICVX) Delisted 10%+ Owner 3,155,169 $15.31 $48.31M $1.00M 1 2021-08-02
Inozyme Pharma, Inc. (INZY) Delisted 10%+ Owner 438,875 $4.00 $1.76M $1.30M 1 2020-07-29
REGN 10%+ Owner 279,766 $695.63 $194.62M -$9.52B 46 2020-06-11
FULC 10%+ Owner 464,285 $3.69 $1.72M $1.50M 1 2019-07-23
MyoKardia, Inc. (MYOK) Delisted 10%+ Owner 0 — — -$121.48M 5 2019-02-15
ALNY 10%+ Owner 10,554,134 $287.14 $3.03B $1.98B 6 2017-06-01
VYGR 2,352,941 $3.10 $7.30M $1.75M 1 2015-11-18
Regulus Therapeutics Inc. (RGLS) Delisted 10%+ Owner 42,115 $8.16 $343.7K $10.00M 1 2014-02-05
HUMANIGEN, INC (KBIO) Delisted 579,030 — — $700.0K 1 2013-02-07
GENZ 10%+ Owner 187,986,225 $38.99 $7.33B $2.48B 1 2011-04-08

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-09-14 Translate Bio, Inc. (TBIO) Delisted Buy (P) +71,983,597 $2.74B EDGAR
2021-08-02 Icosavax, Inc. (ICVX) Delisted Mixed +3,155,169 $1.00M EDGAR
2020-07-29 Inozyme Pharma, Inc. (INZY) Delisted Mixed +520,125 $1.30M EDGAR
2020-06-11 REGN Sell (S) −120,234 -$71.84M EDGAR
2020-05-29 REGN Sell (S) −22,821,451 -$11.64B EDGAR
2020-03-11 REGN Sell (S) −128,914 -$63.12M EDGAR
2019-09-12 REGN Sell (S) −172,904 -$48.61M EDGAR
2019-07-23 FULC Mixed +558,035 $1.50M EDGAR
2019-03-12 REGN Sell (S) −131,115 -$54.04M EDGAR
2019-02-15 MyoKardia, Inc. (MYOK) Delisted Sell (S) −4,168,899 -$157.00M EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.